Edition:
India

Orgenesis Inc (ORGS.OQ)

ORGS.OQ on NASDAQ Stock Exchange Capital Market

5.00USD
22 Mar 2019
Change (% chg)

$-0.10 (-1.96%)
Prev Close
$5.10
Open
$5.11
Day's High
$5.11
Day's Low
$4.98
Volume
9,135
Avg. Vol
9,201
52-wk High
$12.10
52-wk Low
$3.87

Latest Key Developments (Source: Significant Developments)

Orgenesis Announces Collaboration With MangoGen Pharma For Advanced Gene Delivery Platform
Wednesday, 19 Dec 2018 

Dec 18 (Reuters) - Orgenesis Inc ::ORGENESIS ANNOUNCES COLLABORATION WITH MANGOGEN PHARMA FOR ADVANCED GENE DELIVERY PLATFORM.ORGENESIS - MANGOGEN COLLABORATION INITIALLY FOCUSED ON PRE-CLINICAL DEVELOPMENT OF INSULIN PRODUCING CELLS USING MANGOGEN'S GENE DELIVERY PLATFORM.  Full Article

Orgenesis Inc says On Oct 22, Board Approved Change To Co's Fiscal Year End From November 30 To December 31 Of Each Year
Friday, 26 Oct 2018 

Oct 25 (Reuters) - Orgenesis Inc ::ORGENESIS INC - ON OCT 22, BOARD APPROVED A CHANGE TO CO'S FISCAL YEAR END FROM NOVEMBER 30 TO DECEMBER 31 OF EACH YEAR - SEC FILING.ORGENESIS INC - CHANGE IN FISCAL YEAR END WILL COMMENCE WITH TWELVE MONTH PERIOD ENDING DECEMBER 31, 2019.  Full Article

Orgenesis Announces Collaboration With Hemogenyx
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Orgenesis Inc ::ORGENESIS ANNOUNCES COLLABORATION WITH HEMOGENYX TO DEVELOP BLOOD STEM CELL REPLACEMENT PRODUCT.ORGENESIS INC - ORGENESIS SHALL MANUFACTURE AND SUPPLY ALL HU-PHEC RELATED PRODUCTS BOTH DURING AND FOLLOWING COMPLETION OF CLINICAL TRIALS.ORGENESIS INC - ORGENESIS SHALL ALSO RECEIVE WORLDWIDE RIGHTS TO MARKET PRODUCTS.ORGENESIS INC - ORGENESIS AND/OR ITS AFFILIATES WILL ADVANCE TO HEMOGENYX A CONVERTIBLE LOAN IN AN AMOUNT OF NO LESS THAN $1.0 MILLION.  Full Article

Orgenesis Announces Collaboration With Immugenyx To Develop And Commercialize Advanced Hematopoietic Chimeras
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Orgenesis Inc ::ORGENESIS ANNOUNCES COLLABORATION WITH IMMUGENYX TO DEVELOP AND COMMERCIALIZE ADVANCED HEMATOPOIETIC CHIMERAS.ORGENESIS INC - ORGENESIS SHALL RECEIVE WORLDWIDE RIGHTS TO MARKET PRODUCTS AND SHALL SERVE AS A GLOBAL DISTRIBUTOR OF IMMUGENYX'S PRODUCTS.ORGENESIS INC - IMMUGENYX WILL COLLABORATE WITH ORGENESIS TO FURTHER DEVELOPMENT AND COMMERCIALIZATION OF ITS ADVANCED HEMATOPOIETIC CHIMERAS.  Full Article

Orgenesis Q3 Loss Per Share $0.35
Monday, 15 Oct 2018 

Oct 15 (Reuters) - Orgenesis Inc ::ORGENESIS REPORTS 143% INCREASE IN REVENUE AND 316% INCREASE IN GROSS PROFIT FOR THE THIRD QUARTER OF FISCAL 2018.Q3 LOSS PER SHARE $0.35.Q3 REVENUE ROSE 143 PERCENT TO $6.2 MILLION.QUARTER ENDED WITH $16.7 MILLION OF CASH AND APPROXIMATELY $30 MILLION OF SHAREHOLDERS' EQUITY.  Full Article

Orgenesis Reports 73 Percent Increase In Revenue For Q2
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Orgenesis Inc ::ORGENESIS REPORTS 73% INCREASE IN REVENUE FOR THE SECOND QUARTER OF FISCAL 2018.Q2 LOSS PER SHARE $0.20.Q2 REVENUE ROSE 73 PERCENT TO $4.0 MILLION.  Full Article

Orgenesis Reports Q1 Loss Per Share Of $0.52
Thursday, 19 Apr 2018 

April 19 (Reuters) - Orgenesis Inc ::ORGENESIS REPORTS 42% INCREASE IN REVENUE FOR THE FIRST QUARTER OF FISCAL 2018.Q1 LOSS PER SHARE $0.52.Q1 REVENUE ROSE 42 PERCENT TO $2.6 MILLION.  Full Article

Orgenesis Files For Mixed Shelf Of Up To $100 Mln
Tuesday, 20 Mar 2018 

March 19 (Reuters) - :ORGENESIS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING‍​.  Full Article